Rank,Term name,P-value,Z-score,Combined score,Overlapping genes,Adjusted p-value,Old p-value,Old adjusted p-value,gene count
1,Prostaglandin Synthesis and Regulation WP98,0.0017297149582948877,21.483870967741936,136.6330935352878,"['HSD11B2', 'ANXA3', 'MITF']",0.08283318173521388,0,0,3
2,Microglia Pathogen Phagocytosis Pathway WP3937,0.002123927736800356,inf,inf,"['C1QA', 'HCK']",0.08283318173521388,0,0,2
3,Arrhythmogenic Right Ventricular Cardiomyopathy WP2118,0.011990697454199936,21.158730158730158,93.59826954372414,"['DSP', 'ITGA8']",0.23381860035689875,0,0,2
4,Histone Modifications WP2369,0.011990697454199936,21.158730158730158,93.59826954372414,"['SMYD1', 'HIST1H3E']",0.23381860035689875,0,0,2
5,Oxidative Damage WP3941,0.028217422659386173,10.563492063492063,37.68859248248718,"['C1QA', 'NFKBIE']",0.2586723069811123,0,0,2
6,Host-pathogen interaction of human coronaviruses - MAPK signaling WP4877,0.028217422659386173,10.563492063492063,37.68859248248718,"['IFITM3', 'IFITM2']",0.2586723069811123,0,0,2
7,Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome WP4320,0.0464283627914817,inf,inf,['HIST1H3E'],0.2586723069811123,0,0,1
8,Effects of nitric oxide WP1995,0.0464283627914817,inf,inf,['AOX1'],0.2586723069811123,0,0,1
9,Interferon type I signaling pathways WP585,0.0464283627914817,inf,inf,['ZAP70'],0.2586723069811123,0,0,1
10,STING pathway in Kawasaki-like disease and COVID-19 WP4961,0.0464283627914817,inf,inf,['NFKBIE'],0.2586723069811123,0,0,1
11,Canonical NF-KB pathway WP4562,0.0464283627914817,inf,inf,['NFKBIE'],0.2586723069811123,0,0,1
12,Type I interferon induction and signaling during SARS-CoV-2 infection WP4868,0.0464283627914817,inf,inf,['TLR9'],0.2586723069811123,0,0,1
13,Glycosaminoglycan degradation WP4815,0.0464283627914817,inf,inf,['HPSE2'],0.2586723069811123,0,0,1
14,Molybdenum cofactor (Moco) biosynthesis WP4507,0.0464283627914817,inf,inf,['AOX1'],0.2586723069811123,0,0,1
15,Epithelial to mesenchymal transition in colorectal cancer WP4239,0.07510371063166116,5.265873015873016,13.632741306823892,"['DSP', 'CLDN9']",0.27301887170506384,0,0,2
16,7-oxo-C and 7beta-HC pathways WP5064,0.09073289023068286,20.84375,50.02156830616748,['HSD11B2'],0.27301887170506384,0,0,1
17,IL-6 signaling pathway WP364,0.09073289023068286,20.84375,50.02156830616748,['HCK'],0.27301887170506384,0,0,1
18,Nicotine Metabolism WP1600,0.09073289023068286,20.84375,50.02156830616748,['AOX1'],0.27301887170506384,0,0,1
19,Simplified Depiction of MYD88 Distinct Input-Output Pathway WP3877,0.09073289023068286,20.84375,50.02156830616748,['TLR9'],0.27301887170506384,0,0,1
20,Iron metabolism in placenta WP2007,0.09073289023068286,20.84375,50.02156830616748,['HEPHL1'],0.27301887170506384,0,0,1
21,T-Cell Receptor and Co-stimulatory Signaling WP2583,0.09073289023068286,20.84375,50.02156830616748,['ZAP70'],0.27301887170506384,0,0,1
22,Bladder cancer WP2828,0.09073289023068286,20.84375,50.02156830616748,['DAPK2'],0.27301887170506384,0,0,1
23,Toll-like Receptor Signaling related to MyD88 WP3858,0.09073289023068286,20.84375,50.02156830616748,['TLR9'],0.27301887170506384,0,0,1
24,Glycogen Synthesis and Degradation WP500,0.09073289023068286,20.84375,50.02156830616748,['PHKA1'],0.27301887170506384,0,0,1
25,Focal Adhesion WP306,0.11914119014919898,3.821067821067821,8.129115517878832,"['HCK', 'ITGA8']",0.27301887170506384,0,0,2
26,IL-3 signaling pathway WP286,0.1330091939075952,10.4140625,21.008673872586154,['HCK'],0.27301887170506384,0,0,1
27,Integrin-mediated Cell Adhesion WP185,0.1330091939075952,10.4140625,21.008673872586154,['ITGA8'],0.27301887170506384,0,0,1
28,Kit receptor signaling pathway WP304,0.1330091939075952,10.4140625,21.008673872586154,['MITF'],0.27301887170506384,0,0,1
29,T-cell receptor (TCR) signaling pathway WP69,0.1330091939075952,10.4140625,21.008673872586154,['ZAP70'],0.27301887170506384,0,0,1
30,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma WP4553,0.1330091939075952,10.4140625,21.008673872586154,['HIST1H3E'],0.27301887170506384,0,0,1
31,Pathogenesis of SARS-CoV-2 Mediated by nsp9-nsp10 Complex WP4884,0.1330091939075952,10.4140625,21.008673872586154,['ZAP70'],0.27301887170506384,0,0,1
32,Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway WP2203,0.1330091939075952,10.4140625,21.008673872586154,['HCK'],0.27301887170506384,0,0,1
33,Genes controlling nephrogenesis WP4823,0.1330091939075952,10.4140625,21.008673872586154,['ITGA8'],0.27301887170506384,0,0,1
34,Chemokine signaling pathway WP3929,0.1330091939075952,10.4140625,21.008673872586154,['HCK'],0.27301887170506384,0,0,1
35,Classical pathway of steroidogenesis with glucocorticoid and mineralocorticoid metabolism WP4523,0.1330091939075952,10.4140625,21.008673872586154,['HSD11B2'],0.27301887170506384,0,0,1
36,Purine metabolism and related disorders WP4224,0.1330091939075952,10.4140625,21.008673872586154,['AOX1'],0.27301887170506384,0,0,1
37,Complement Activation WP545,0.1330091939075952,10.4140625,21.008673872586154,['C1QA'],0.27301887170506384,0,0,1
38,Development of ureteric collection system WP5053,0.1330091939075952,10.4140625,21.008673872586154,['ITGA8'],0.27301887170506384,0,0,1
39,Nephrotic syndrome WP4758,0.17334872481255104,6.9375,12.157621618461702,['EMP2'],0.2759428680689588,0,0,1
40,Endochondral Ossification with Skeletal Dysplasias WP4808,0.17334872481255104,6.9375,12.157621618461702,['CTSV'],0.2759428680689588,0,0,1
41,Endochondral Ossification WP474,0.17334872481255104,6.9375,12.157621618461702,['CTSV'],0.2759428680689588,0,0,1
42,Amyotrophic lateral sclerosis (ALS) WP2447,0.17334872481255104,6.9375,12.157621618461702,['NEFH'],0.2759428680689588,0,0,1
43,Apoptosis WP254,0.17334872481255104,6.9375,12.157621618461702,['NFKBIE'],0.2759428680689588,0,0,1
44,T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection WP3863,0.17334872481255104,6.9375,12.157621618461702,['ZAP70'],0.2759428680689588,0,0,1
45,Cancer immunotherapy by PD-1 blockade WP4585,0.17334872481255104,6.9375,12.157621618461702,['ZAP70'],0.2759428680689588,0,0,1
46,Toll-like Receptor Signaling Pathway WP75,0.17334872481255104,6.9375,12.157621618461702,['TLR9'],0.2759428680689588,0,0,1
47,RANKL/RANK signaling pathway WP2018,0.17334872481255104,6.9375,12.157621618461702,['MITF'],0.2759428680689588,0,0,1
48,Hippo-Merlin Signaling Dysregulation WP4541,0.17334872481255104,6.9375,12.157621618461702,['ITGA8'],0.2759428680689588,0,0,1
49,DNA damage response (only ATM dependent) WP710,0.17334872481255104,6.9375,12.157621618461702,['BIK'],0.2759428680689588,0,0,1
50,Inflammatory Response Pathway WP453,0.21183888283282987,5.19921875,8.06881981064671,['ZAP70'],0.31176288416907033,0,0,1
51,Lung fibrosis WP3624,0.21183888283282987,5.19921875,8.06881981064671,['DSP'],0.31176288416907033,0,0,1
52,Matrix Metalloproteinases WP129,0.21183888283282987,5.19921875,8.06881981064671,['MMP26'],0.31176288416907033,0,0,1
53,Modulators of TCR signaling and T cell activation WP5072,0.21183888283282987,5.19921875,8.06881981064671,['ZAP70'],0.31176288416907033,0,0,1
54,Neural Crest Differentiation WP2064,0.2485631860295767,4.15625,5.785741877248845,['MITF'],0.32860895780181326,0,0,1
55,Allograft Rejection WP2328,0.2485631860295767,4.15625,5.785741877248845,['C1QA'],0.32860895780181326,0,0,1
56,Apoptosis Modulation and Signaling WP1772,0.2485631860295767,4.15625,5.785741877248845,['BIK'],0.32860895780181326,0,0,1
57,TNF-alpha signaling pathway WP231,0.2485631860295767,4.15625,5.785741877248845,['NFKBIE'],0.32860895780181326,0,0,1
58,Heart Development WP1591,0.2485631860295767,4.15625,5.785741877248845,['SMYD1'],0.32860895780181326,0,0,1
59,Regulation of toll-like receptor signaling pathway WP1449,0.2485631860295767,4.15625,5.785741877248845,['TLR9'],0.32860895780181326,0,0,1
60,Prolactin Signaling Pathway WP2037,0.2836014388411929,3.4609375,4.3614229453603786,['ZAP70'],0.36263790540349256,0,0,1
61,Ras signaling WP4223,0.2836014388411929,3.4609375,4.3614229453603786,['ZAP70'],0.36263790540349256,0,0,1
62,Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.3489214090138183,2.591796875,2.728925144524685,['NEFH'],0.41236166519814893,0,0,1
63,Pathways in clear cell renal cell carcinoma WP4018,0.3489214090138183,2.591796875,2.728925144524685,['LDHC'],0.41236166519814893,0,0,1
64,Melanoma WP4685,0.3489214090138183,2.591796875,2.728925144524685,['MITF'],0.41236166519814893,0,0,1
65,Cell cycle WP179,0.3489214090138183,2.591796875,2.728925144524685,['CDC14A'],0.41236166519814893,0,0,1
66,Tryptophan metabolism WP465,0.3489214090138183,2.591796875,2.728925144524685,['AOX1'],0.41236166519814893,0,0,1
67,Calcium Regulation in the Cardiac Cell WP536,0.3793455928140027,2.3020833333333335,2.231426951396721,['GJD2'],0.4351317094042972,0,0,1
68,Glycolysis and Gluconeogenesis WP534,0.3793455928140027,2.3020833333333335,2.231426951396721,['LDHC'],0.4351317094042972,0,0,1
69,Complement and Coagulation Cascades WP558,0.4083689504437522,2.0703125,1.8541392114701984,['C1QA'],0.4616344657190242,0,0,1
70,Glucocorticoid Receptor Pathway WP2880,0.4360550181360154,1.8806818181818181,1.5609411879211537,['SRGN'],0.48588987735156003,0,0,1
71,NRF2 pathway WP2884,0.48765536347779215,1.5889423076923077,1.1410931106899602,['SLC5A3'],0.5357340612854619,0,0,1
72,Nuclear Receptors Meta-Pathway WP2882,0.5054711497338146,1.214752567693744,0.8287823283494961,"['SRGN', 'SLC5A3']",0.5475937455449658,0,0,2
73,Complement system WP2806,0.5564579542780866,1.2880859375,0.7550291739326016,['FCGR3A'],0.5945715127902844,0,0,1
74,Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways WP706,0.5773040542186947,1.2113970588235294,0.6655248198311321,['CDCA7L'],0.6085096787710566,0,0,1
75,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.6161441613481254,1.082236842105263,0.5240995050172494,['ITGA8'],0.6407899278020505,0,0,1
76,PI3K-Akt signaling pathway WP4172,0.6514652704221179,0.9776785714285714,0.4189657625723068,['ITGA8'],0.6686090933279631,0,0,1
77,IL-18 signaling pathway WP4754,0.7516714841208,0.7293526785714286,0.2081980301686833,['NFKBIE'],0.7614334514470441,0,0,1
78,VEGFA-VEGFR2 Signaling Pathway WP3888,0.8683060074459544,0.49314024390243905,0.06963686806522978,['CLIC1'],0.8683060074459544,0,0,1
